Skip to content
PubMed This is a summary of 6 peer-reviewed journal articles Updated
Nephrology · Autosomal Dominant Tubulointerstitial Kidney Disease, SEC61A1-Related

Diagnosis and Genetics of ADTKD-SEC61A1

At a Glance

ADTKD-SEC61A1 is usually confirmed by finding a pathogenic SEC61A1 variant on a kidney gene panel or exome test, not by kidney biopsy alone. A de novo result can occur without family history, and genetic counseling helps explain inheritance and family-planning risks.

Getting to the bottom of an ultra-rare condition like ADTKD-SEC61A1 is a journey that often requires specialized tools. Because the symptoms can overlap with many other kidney issues, a standard physical exam or routine blood work is rarely enough to provide a definitive answer.

Why Biopsies Are Not the Answer

In many kidney diseases, a kidney biopsy (taking a tiny piece of tissue to look at under a microscope) is the “gold standard” for diagnosis. However, for ADTKD-SEC61A1, a biopsy is often non-specific and cannot confirm the disease [1][2].

The microscope might show generic signs of “wear and tear,” such as tubulointerstitial fibrosis (scarring between the kidney’s filtering tubes) or glomerulosclerosis (scarring of the glomeruli, the kidney’s actual filtering units) [1][3]. While these findings tell the doctor the kidney is struggling, they cannot tell the doctor why. In some cases, the tissue may even look relatively normal or show unusual, nonspecific signs like tubular dysgenesis (abnormal development of the tubes), which still doesn’t point specifically to the SEC61A1 gene [1]. Because a biopsy cannot definitively confirm or rule out this specific condition, modern guidelines recommend prioritizing genetic testing instead [3][1].

Genetic Testing: The Definitive Map

The standard confirmatory route for diagnosing ADTKD-SEC61A1 is through genetic testing [4]. This test analyzes DNA to look for a pathogenic variant (a “spelling error”) in the SEC61A1 gene. Doctors typically use a kidney gene panel, which looks at many genes known to cause kidney disease, or exome sequencing, which looks at all the protein-coding genes in the body [5]. Keep in mind that a negative panel does not perfectly exclude a genetic cause, as some testing methods may miss certain structural or deep-intronic variants.

Understanding Inheritance: “De Novo” vs. Familial

Most people assume that a genetic disease must be inherited from a parent, but that is not always the case with ADTKD-SEC61A1.

  • Autosomal Dominant: This means a person only needs one mutated copy of the gene (from either parent) to have the condition [3]. In dominant conditions, the term “carrier” is usually not used, as anyone with the variant typically has the disease. An affected individual generally has a 50% chance of passing the pathogenic variant to each future child.
  • De Novo Mutations: A significant number of individuals with ADTKD-SEC61A1 have a de novo mutation [6][1]. This means the mutation happened spontaneously in the patient; it was not passed down from either the mother or the father.
  • Family Planning: Because of these spontaneous mutations, a lack of family history does not rule out ADTKD-SEC61A1. However, even if a variant is de novo in a child, the parents still have a small risk of recurrence for future children due to a rare phenomenon called germline mosaicism (where the mutation is present in a parent’s reproductive cells but not in their blood). Parental targeted testing and formal genetic counseling are highly recommended to discuss reproductive options and cascade testing for relatives.

Reading the Genetic Report

When you receive a genetic test report, it is crucial to interpret the results with a clinical geneticist, genetic counselor, and nephrologist. Here are three key terms to look for:

  1. Variant Classification: Look for the word Pathogenic. This means the lab is highly confident this specific mutation causes the disease [4]. A Likely Pathogenic result is a probabilistic laboratory classification, not absolute proof. A Variant of Uncertain Significance (VUS) means there is not enough evidence to classify the variant as harmful or benign. A VUS should not be used to make treatment decisions, guide predictive testing, or exclude living kidney donors.
  2. Zygosity: For ADTKD-SEC61A1, the report should say Heterozygous, meaning one of the two copies of the gene is mutated [6].
  3. Protein Change: You might see a code like p.Ser71Pro or p.Phe458Val. This identifies exactly where the “spelling error” occurred in the protein [6][1]. Knowing this specific code can help you connect with other families who have the exact same variant.

Common questions in this guide

What test is usually used to diagnose ADTKD-SEC61A1?
ADTKD-SEC61A1 is usually confirmed by genetic testing that identifies a pathogenic SEC61A1 variant. Doctors may use a kidney disease gene panel or exome sequencing, while a kidney biopsy is often nonspecific and cannot confirm the condition by itself.
Can a kidney biopsy confirm ADTKD-SEC61A1?
Usually, no. A biopsy may show kidney scarring or other changes, but these findings can occur in many kidney diseases and cannot reliably confirm or rule out SEC61A1-related disease.
What does a heterozygous SEC61A1 result mean?
Heterozygous means that one of the two copies of the SEC61A1 gene has a variant. Because ADTKD-SEC61A1 is autosomal dominant, one disease-causing copy can be enough to cause the condition.
Can ADTKD-SEC61A1 occur when no one else in the family has it?
Yes. A de novo variant can arise spontaneously in a person rather than being inherited from either parent, so a negative family history does not rule out ADTKD-SEC61A1. An affected person generally has a 50% chance of passing the variant to each future child.
What should I do if my report says VUS?
A Variant of Uncertain Significance, or VUS, means there is not enough evidence to determine whether the variant causes disease. It should not be used by itself to make treatment decisions, guide predictive testing, or exclude a living kidney donor; ask a genetics professional about future re-evaluation.
Does a negative kidney gene panel rule out a genetic cause?
No. Some testing methods may miss certain changes, including structural or deep-intronic variants, so a negative panel does not completely exclude a genetic cause. A nephrologist or genetics professional can explain whether additional testing is appropriate.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on tubulointerstitial kidney disease, autosomal dominant 6.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Could you explain what 'heterozygous' and 'de novo' mean specifically in the context of this genetic report?
  2. 2.Since this is a de novo mutation in the patient, what is the exact recurrence risk for parents due to germline mosaicism, and what are the risks for the patient's future children?
  3. 3.Was a full comprehensive kidney gene panel performed, or was this a targeted test just for SEC61A1?
  4. 4.If the report shows a 'Variant of Uncertain Significance' (VUS), what are the next steps for re-evaluating this in the future?
  5. 5.How can we best coordinate cascade testing and genetic counseling for other family members?

References

References (6)
  1. 1

    Hypoaldosteronism due to a novel SEC61A1 variant successfully treated with fludrocortisone.

    Karpman D, Lindström ML, Möller M, et al.

    Clinical kidney journal 2024; (17(8)):sfae213 doi:10.1093/ckj/sfae213.

    PMID: 39135939
  2. 2

    Two sides of the same coin: a complex presentation of autosomal dominant tubulointerstitial kidney diseases: a literature review and case reports.

    Fistrek Prlic M, Huljev Frkovic S, Beck B, et al.

    Frontiers in pediatrics 2023; (11()):1283325 doi:10.3389/fped.2023.1283325.

    PMID: 38027261
  3. 3

    Heterozygous Loss-of-Function SEC61A1 Mutations Cause Autosomal-Dominant Tubulo-Interstitial and Glomerulocystic Kidney Disease with Anemia.

    Bolar NA, Golzio C, Živná M, et al.

    American journal of human genetics 2016; (99(1)):174-87.

    PMID: 27392076
  4. 4

    Familial juvenile hyperuricemic nephropathy: Revisiting the SLC8A1 gene, in a family with a novel terminal gross deletion in the UMOD gene.

    Gonçalves F, Lisboa-Gonçalves P, Quental R, et al.

    Nefrologia 2024; (44(4)):576-581 doi:10.1016/j.nefroe.2024.08.002.

    PMID: 39216982
  5. 5

    Diverse molecular causes of unsolved autosomal dominant tubulointerstitial kidney diseases.

    Wopperer FJ, Knaup KX, Stanzick KJ, et al.

    Kidney international 2022; (102(2)):405-420 doi:10.1016/j.kint.2022.04.031.

    PMID: 35643372
  6. 6

    De novo SEC61A1 mutation in congenital anemia and early-onset kidney disease: Case report and review of the literature.

    Zhong L, Ding J, Ma M, et al.

    Gene 2026; (993()):150106 doi:10.1016/j.gene.2026.150106.

    PMID: 41850665

This page explains ADTKD-SEC61A1 diagnosis and genetic reports for informational purposes only and does not constitute medical advice. A nephrologist and genetics professional should interpret individual results and discuss family-planning decisions.